102 related articles for article (PubMed ID: 8104123)
1. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients.
Lee P; Mohammed N; Marshall L; Abeysinghe RD; Hider RC; Porter JB; Singh S
Drug Metab Dispos; 1993; 21(4):640-4. PubMed ID: 8104123
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in rats.
Epemolu OR; Singh S; Hider RC; Damani LA
Drug Metab Dispos; 1992; 20(5):736-41. PubMed ID: 1358580
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and pharmacokinetics of 1-(2'-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat.
Choudhury R; Epemolu RO; Rai BL; Hider RC; Singh S
Drug Metab Dispos; 1997 Mar; 25(3):332-9. PubMed ID: 9172951
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid.
Dalgaard L; Hjortkjaer RK; Regnier B; Nordholm L
Drug Metab Dispos; 1994; 22(2):289-93. PubMed ID: 7912178
[TBL] [Abstract][Full Text] [Related]
5. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
Lombardo T; Ferro G; Frontini V; Percolla S
Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
[TBL] [Abstract][Full Text] [Related]
6. Toxicokinetics of deltamethrin and its 4'-HO-metabolite in the rat.
Anadón A; Martinez-Larrañaga MR; Fernandez-Cruz ML; Diaz MJ; Fernandez MC; Martinez MA
Toxicol Appl Pharmacol; 1996 Nov; 141(1):8-16. PubMed ID: 8917670
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
[TBL] [Abstract][Full Text] [Related]
8. Development of an intravenous desferrioxamine mesylate treatment protocol for swine: monitoring of desferrioxamine and metabolites by high-performance liquid chromatography.
Fisher EA; McLachlan DR; Kruck TP; Mustard RA
Pharmacology; 1990; 41(5):263-71. PubMed ID: 2092330
[TBL] [Abstract][Full Text] [Related]
9. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
Porter JB; Rafique R; Srichairatanakool S; Davis BA; Shah FT; Hair T; Evans P
Ann N Y Acad Sci; 2005; 1054():155-68. PubMed ID: 16339661
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of vinblastine by continuous intravenous infusion.
Lu K; Yap HY; Loo TL
Cancer Res; 1983 Mar; 43(3):1405-8. PubMed ID: 6825110
[TBL] [Abstract][Full Text] [Related]
11. Desferrioxamine release from gelatin-based systems.
Ulubayram K; Kiziltay A; Yilmaz E; Hasirci N
Biotechnol Appl Biochem; 2005 Dec; 42(Pt 3):237-45. PubMed ID: 15984929
[TBL] [Abstract][Full Text] [Related]
12. Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine.
Olivieri NF; Berriman AM; Tyler BJ; Davis SA; Francombe WH; Liu PP
Am J Hematol; 1992 Sep; 41(1):61-3. PubMed ID: 1503101
[TBL] [Abstract][Full Text] [Related]
13. Urinary zinc excretion and zinc status of patients with beta-thalassemia major.
Aydinok Y; Coker C; Kavakli K; Polat A; Nisli G; Cetiner N; Kantar M; Cetingül N
Biol Trace Elem Res; 1999 Nov; 70(2):165-72. PubMed ID: 10535525
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
15. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and absolute bioavailability of epristeride in healthy male subjects.
Benincosa LJ; Audet PR; Lundberg D; Zariffa N; Jorkasky DK
Biopharm Drug Dispos; 1996 Apr; 17(3):249-58. PubMed ID: 8983399
[TBL] [Abstract][Full Text] [Related]
17. Intensification of chelating-therapy in patients with thalassemia major.
Laws HJ; Göbel U; Christaras A; Janssen G
Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
[TBL] [Abstract][Full Text] [Related]
18. Successful desensitization of a case with desferrioxamine hypersensitivity.
Gülen F; Demir E; Tanaç R; Aydinok Y; Gulen H; Yenigün A; Can D
Minerva Pediatr; 2006 Dec; 58(6):571-4. PubMed ID: 17093379
[TBL] [Abstract][Full Text] [Related]
19. Disposition and metabolism of finasteride in dogs.
Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ
Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636
[TBL] [Abstract][Full Text] [Related]
20. Plasma elimination of indocyanine green in the intact pig after bolus injection and during constant infusion: comparison of spectrophotometry and high-pressure liquid chromatography for concentration analysis.
Ott P; Keiding S; Bass L
Hepatology; 1993 Dec; 18(6):1504-15. PubMed ID: 8244277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
